File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer

TitleA phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer
Authors
Issue Date2007
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.amjclinicaloncology.com
Citation
American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, v. 30 n. 2, p. 133-138 How to Cite?
AbstractThe objective of the present study is to investigate the clinical efficacy and tolerance of vinorelbine and pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) with prior taxane and/or anthracycline treatment. A total of 25 patients who previously received taxane- and/or anthracycline-based chemotherapy as first- and/or second-line treatment of MBC were entered into the study and were treated with 20 mg/m2 vinorelbine on day 1 and 8 and 30 mg/m2 PLD on day 1 every 3 weeks. All were evaluated for efficacy, quality of life, and tolerance. Three complete and 6 partial responses were observed in 25 patients for an objective response rate of 36% (95% confidence interval: 17-55%). Eight patients (32%) had stable disease of not less than 3 months and 8 patients (32%) had disease progression. The median progression-free survival was 6.7 months (range, 2-18 months), and the median overall survival was 13.2 months (range, 3-31 months). Severe toxicities (grade 3 or above) were neutropenia (16%) and mucositis (8%). The health-related quality of life assessed before each cycle by specific questionnaire did not differ significantly over the treatment period. The combination of vinorelbine and PLD for anthracycline- and/or taxane-pretreated patients with MBC is an active and safe regimen that does not compromise the quality of life.
Persistent Identifierhttp://hdl.handle.net/10722/192067
ISSN
2015 Impact Factor: 2.977
2015 SCImago Journal Rankings: 0.846
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChow, LWC-
dc.contributor.authorYip, AYS-
dc.contributor.authorLang, BHH-
dc.date.accessioned2013-10-17T01:21:08Z-
dc.date.available2013-10-17T01:21:08Z-
dc.date.issued2007-
dc.identifier.citationAmerican Journal of Clinical Oncology: Cancer Clinical Trials, 2007, v. 30 n. 2, p. 133-138-
dc.identifier.issn0277-3732-
dc.identifier.urihttp://hdl.handle.net/10722/192067-
dc.description.abstractThe objective of the present study is to investigate the clinical efficacy and tolerance of vinorelbine and pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) with prior taxane and/or anthracycline treatment. A total of 25 patients who previously received taxane- and/or anthracycline-based chemotherapy as first- and/or second-line treatment of MBC were entered into the study and were treated with 20 mg/m2 vinorelbine on day 1 and 8 and 30 mg/m2 PLD on day 1 every 3 weeks. All were evaluated for efficacy, quality of life, and tolerance. Three complete and 6 partial responses were observed in 25 patients for an objective response rate of 36% (95% confidence interval: 17-55%). Eight patients (32%) had stable disease of not less than 3 months and 8 patients (32%) had disease progression. The median progression-free survival was 6.7 months (range, 2-18 months), and the median overall survival was 13.2 months (range, 3-31 months). Severe toxicities (grade 3 or above) were neutropenia (16%) and mucositis (8%). The health-related quality of life assessed before each cycle by specific questionnaire did not differ significantly over the treatment period. The combination of vinorelbine and PLD for anthracycline- and/or taxane-pretreated patients with MBC is an active and safe regimen that does not compromise the quality of life.-
dc.languageeng-
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.amjclinicaloncology.com-
dc.relation.ispartofAmerican Journal of Clinical Oncology: Cancer Clinical Trials-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - toxicity-
dc.subject.meshBreast Neoplasms - drug therapy - mortality - pathology-
dc.subject.meshDoxorubicin - administration and dosage - analogs and derivatives - therapeutic use - toxicity-
dc.subject.meshNeoplasm Metastasis - drug therapy - pathology-
dc.subject.meshPolyethylene Glycols - administration and dosage - therapeutic use - toxicity-
dc.titleA phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast canceren_US
dc.typeArticleen_US
dc.identifier.emailLang, BHH: blang@hkucc.hku.hk-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.coc.0000251400.47711.fe-
dc.identifier.pmid17414461-
dc.identifier.scopuseid_2-s2.0-34147127552-
dc.identifier.hkuros136161-
dc.identifier.hkuros226754-
dc.identifier.hkuros226719-
dc.identifier.volume30-
dc.identifier.issue2-
dc.identifier.spage133-
dc.identifier.epage138-
dc.identifier.isiWOS:000245637100005-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats